Website
Neuren Pharmaceuticals (ASX:NEU) is a clinical-stage biopharmaceutical company focused on developing therapies for neurodevelopmental disorders, including Rett syndrome and Fragile X syndrome.
Neuren’s lead candidate, trofinetide, is a synthetic analog of the amino-terminal tripeptide of IGF-1, shown to improve symptoms of Rett syndrome. The compound has received Fast Track and Orphan Drug designations from the FDA and has been approved as DAYBUE™ the FDA for Rett syndrome.
